Hetero Valsartan $11.37M Drug Settlement — Idaho Residents
This settlement covers U.S. residents nationwide, including Idaho. Check your eligibility and file your claim before the deadline.
Idaho Eligibility
Class members must meet all of the following criteria: They are an individual in the United States, its territories or possessions. They paid any amount of money for retail purchases of Valsartan finished drug formulations that used the Hetero Process III Valsartan active pharmaceutical ingredient. They made the purchase between May 1, 2018, and July 31, 2018. Class members can check the National Drug Code on their prescription bottle or pharmacy records to determine if their medication qualifies. Qualifying prescriptions may include National Drug Codes 31722-747-90 (160mg) and 31722-748-90 (320mg). Pharmacy benefit managers do not qualify for this settlement.
About This Settlement
Consumers who bought Hetero Valsartan between May 1, 2018, and July 31, 2018, may be eligible to claim a cash payment from a class action settlement.
Who Is Eligible?
Class members must meet all of the following criteria: They are an individual in the United States, its territories or possessions. They paid any amount of money for retail purchases of Valsartan finished drug formulations that used the Hetero Process III Valsartan active pharmaceutical ingredient. They made the purchase between May 1, 2018, and July 31, 2018. Class members can check the National Drug Code on their prescription bottle or pharmacy records to determine if their medication qualifies. Qualifying prescriptions may include National Drug Codes 31722-747-90 (160mg) and 31722-748-90 (320mg). Pharmacy benefit managers do not qualify for this settlement.
Claim Details
- Payout
- $11,370,000
- Deadline
- June 2, 2026 (32 days)
- Proof Needed
- No — self-certification
- Category
- Healthcare
More Idaho Settlements
Frequently Asked Questions — Idaho Residents
Settlement data sourced from court records and official settlement administrators. Last verified: May 2, 2026.
